Listen to Gynecologic Oncology

Cologuard-like test for identification of endometrial cancer through vaginal sampling

25 min · 13 de may de 2026
Portada del episodio Cologuard-like test for identification of endometrial cancer through vaginal sampling

Descripción

Editor's Choice:  Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding [https://www.gynecologiconcology-online.net/article/S0090-8258(26)01933-5/abstract] Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice [https://www.gynecologiconcology-online.net/article/S0090-8258(26)01959-1/abstract] Hosted by:  Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USA Featuring:  Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA John B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA Joy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Listen to Gynecologic Oncology!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

69 episodios

episode Cologuard-like test for identification of endometrial cancer through vaginal sampling artwork

Cologuard-like test for identification of endometrial cancer through vaginal sampling

Editor's Choice:  Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding [https://www.gynecologiconcology-online.net/article/S0090-8258(26)01933-5/abstract] Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice [https://www.gynecologiconcology-online.net/article/S0090-8258(26)01959-1/abstract] Hosted by:  Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USA Featuring:  Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA John B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA Joy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

13 de may de 202625 min
episode PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast artwork

PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast

UPDATES IN US FOOD AND DRUG ADMINISTRATION APPROVALS FOR POLY-ADP-RIBOSE POLYMERASE INHIBITORS IN OVARIAN CANCER: A SOCIETY OF GYNECOLOGIC ONCOLOGY CLINICAL PRACTICE REVIEW [https://www.gynecologiconcology-online.net/article/S0090-8258(25)01115-1/fulltext] MODERATOR: URSULA A. MATULONIS, MD; DANA-FARBER CANCER INSTITUTE SPEAKERS: BHAVANA POTHURI, MD; PERLMUTTER CANCER CENTER, NYU LANGONE HEALTH RÓISÍN E. O’CEARBHAILL, MD; GYNECOLOGIC MEDICAL ONCOLOGY, DEPARTMENT OF MEDICINE, MEMORIAL SLOAN KETTERING CANCER CENTER; DEPARTMENT OF MEDICINE, WEILL CORNELL MEDICAL COLLEGE YVETTE DREW, MBBS, PHD; BC CANCER CENTRE VANCOUVER AND UNIVERSITY OF BRITISH COLUMBIA CHRISTINA WASHINGTON, MD; STEPHENSON CANCER CENTER, UNIVERSITY OF OKLAHOMA URSULA A. MATULONIS, MD, IS JOINED BY BHAVANA POTHURI, MD, RÓISÍN O’CEARBHAILL, MD, YVETTE DREW, MBBS, PHD, AND CHRISTINA WASHINGTON, MD, TO DISCUSS RECENT UPDATES IN US FOOD AND DRUG ADMINISTRATION APPROVALS FOR POLY-ADP-RIBOSE POLYMERASE INHIBITORS (PARPI) IN OVARIAN CANCER. BASED ON THE RECENT SOCIETY OF GYNECOLOGIC ONCOLOGY CLINICAL PRACTICE REVIEW PUBLISHED IN GYNECOLOGIC ONCOLOGY, THE SPEAKERS REVIEW THE EVOLVING ROLE OF PARP INHIBITORS AND THE CLINICAL IMPLICATIONS OF UPDATED REGULATORY APPROVALS. THE PANEL EXPLORES CURRENT EVIDENCE SUPPORTING PARP INHIBITOR USE IN OVARIAN CANCER, INCLUDING CONSIDERATIONS FOR PATIENT SELECTION, BIOMARKER TESTING, MAINTENANCE THERAPY, AND SAFETY CONSIDERATIONS. THE SPEAKERS ALSO DISCUSS HOW RECENT CHANGES IN FDA INDICATIONS MAY AFFECT CLINICAL DECISION-MAKING AND TREATMENT SEQUENCING IN PRACTICE. THIS PODCAST HIGHLIGHTS PRACTICAL CLINICAL PEARLS TO HELP GUIDE PRACTITIONERS IN THE APPROPRIATE INTEGRATION OF PARP INHIBITORS INTO THE MANAGEMENT OF OVARIAN CANCER PATIENTS. THIS PODCAST WAS DEVELOPED BY THE SOCIETY OF GYNECOLOGIC ONCOLOGY FOR GYNECOLOGIC ONCOLOGY. Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

8 de may de 202619 min
episode Home the Same Day? Testing the Limits in Ovarian Cancer Debulking Surgery artwork

Home the Same Day? Testing the Limits in Ovarian Cancer Debulking Surgery

Editor's Choice:  Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer [https://www.gynecologiconcology-online.net/article/S0090-8258(26)00802-4/abstract] Editorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection [https://www.gynecologiconcology-online.net/article/S0090-8258(26)00849-8/abstract] Hosted by:  Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada Featuring:  Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA Alexander Melamed, MD MPH, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA Jose Alejandro Rauh-Hain, MD MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

9 de abr de 202618 min
episode In good SHAPE artwork

In good SHAPE

Editor's Choice:  Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial [https://www.gynecologiconcology-online.net/article/S0090-8258(26)00001-6/fulltext] Editorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cancer Trials Group Cx.5/SHAPE trial [https://www.gynecologiconcology-online.net/article/S0090-8258(26)00789-4/abstract] Hosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada Featuring: Janice S. Kwon  MD, MPH, FRCSC, University of British Columbia, Vancouver, Canada and  R. Wendel Naumann, MD Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28203, USA Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

1 de feb de 202623 min